Chimeric antigen receptor T-cell therapy for the community oncologist

Oncologist

Volumn 21, Issue 5, 2016, Pages 608-617

  Maus, Marcela V ^a   Levine, Bruce L ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antigen receptors; Immunotherapy; Leukemia; T lymphocytes

Indexed keywords

BLINATUMOMAB; CD28 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 10; INTERLEUKIN 6; JCAR014; JCAR015; JCAR017; KTE 19; OFATUMUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; RITUXIMAB; T LYMPHOCYTE RECEPTOR; TISAGENLECLEUCEL T; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; UNCLASSIFIED DRUG; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; B CELL LYMPHOMA; CANCER RESEARCH; CELL THERAPY; CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); DISEASE CONTROL; FOLLICULAR LYMPHOMA; IMMUNOLOGICAL TOLERANCE; LARGE CELL LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MORBIDITY; MORTALITY; NONHODGKIN LYMPHOMA; PATIENT CARE; PATIENT SELECTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ADOPTIVE IMMUNOTHERAPY; GENETICS; HUMAN; IMMUNOLOGY; LEUKEMIA, B-CELL; ONCOLOGIST; PROCEDURES;

HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA, B-CELL; ONCOLOGISTS; PATIENT SELECTION; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84966405174     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0421     Document Type: Article

References (99)

1. Galon J, Pages F, Marincola FM et al. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012;10:1.
2. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion. Science 2011; 331:1565–1570.
3. Koulova L, Clark EA, Shu G et al. The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD41 T cells. J Exp Med 1991; 173:759–762.
4. De Benedette MA, Shahinian A, Mak TW et al. Costimulation of CD28- T lymphocytes by 4-1BB ligand. J Immunol 1997;158:551–559.
5. Lu B, Finn OJ. T-cell death and cancer immune tolerance. Cell Death Differ 2008;15:70–79.
6. Duttagupta PA, Boesteanu AC, Katsikis PD. Costimulation signals for memory CD81 T cells during viral infections. Crit Rev Immunol 2009;29: 469–486.
7. Sautès-Fridman C, Cherfils-Vicini J, Damotte D et al. Tumor microenvironment is multifaceted. Cancer Metastasis Rev 2011;30:13–25.
8. Chen Q, Daniel V, Maher DW et al. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 1994;56:755–760.
9. Tada T, Ohzeki S, Utsumi K et al. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol 1991;146:1077–1082.
10. Redmond WL, Linch SN, Kasiewicz MJ. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity. Cancer Immunol Res 2014;2:142–153.
11. Intlekofer AM, Thompson CB. At the bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol 2013;94: 25–39.
12. Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 2013;94:41–53.
13. Dong H, Strome SE, Salomao DR et al. Tumorassociated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002;8:793–800.
14. Weiner LM, Surana R, Wang S. Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010;10:317–327.
15. Kufer P, Lutterbüse R, Baeuerle PA. The promise of bispecific antibodies. Discov Med 2004; 4:325–332.
16. Klinger M, Brandl C, Zugmaier G et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/ CD3-bispecific BiTE antibody blinatumomab. Blood 2012;119:6226–6233.
17. Badoux XC, Keating MJ, Wang X et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 2011;117: 3016–3024.
18. Wierda WG, Kipps TJ, Mayer J et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749–1755.
19. Kirkwood JM, Butterfield LH, Tarhini AA et al. Immunotherapy of cancer in 2012. CA Cancer J Clin 2012;62:309–335.
20. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: Harnessing the T cell response. Nat RevImmunol 2012;12:269–281.
21. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314:126–129.
22. Parkhurst MR, Yang JC, Langan RC et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011;19: 620–626.
23. Stanislawski T, Voss RH, Lotz C et al. Circumventing tolerance to ahumanMDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2001;2: 962–970.
24. Xue SA, Gao L, Hart D et al. Elimination of human leukemia cells in NOD/SCID mice by WT1- TCR gene-transduced human T cells. Blood 2005; 106:3062–3067.
25. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 1989;86:10024–10028.
26. Eshhar Z, Waks T, Gross G et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993;90:720–724.
27. Chmielewski M, Hombach AA, Abken H. Antigen-specific T-cell activation independently of the MHC: Chimeric antigen receptor-redirected T cells. Front Immunol 2013;4:371.
28. Hombach A, Köhler H, Rappl G et al. Human CD41T cells lyse target cells via granzyme/perforin upon circumvention of MHC class II restriction by an antibody-like immunoreceptor. J Immunol 2006; 177:5668–5675.
29. Hombach A, Heuser C, Marquardt T et al. CD41 T cells engrafted with a recombinant immunoreceptor efficiently lyse target cells in a MHC antigen- and Fas-independent fashion. J Immunol 2001;167: 1090–1096.
30. Kreuwel HT, Morgan DJ, Krahl T et al. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD81 T cellmediated insulin-dependent diabetes mellitus. J Immunol 1999;163:4335–4341.
31. June CH, Maus MV, Plesa G et al. Engineered T cells for cancer therapy. Cancer Immunol Immunother 2014;63:969–975.
32. Kalos M, Levine BL, Porter DL et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3:95ra73.
33. Kershaw MH, Westwood JA, Parker LL et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006;12:6106–6115.
34. Lamers CH, Sleijfer S, Vulto AG et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience. J Clin Oncol 2006;24:e20–e22.
35. Till BG, Jensen MC, Wang J et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008;112:2261–2271.
36. Savoldo B, Ramos CA, Liu E et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011;121: 1822–1826.
37. Finney HM, Lawson AD, Bebbington CR et al. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 1998;161:2791–2797.
38. Maher J, Brentjens RJ, Gunset G et al. HumanTlymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol 2002;20:70–75.
39. Sadelain M, Rivière I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003;3:35–45.
40. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013;3:388–398.
41. Kershaw MH, Westwood JA, Slaney CY et al. Clinical application of genetically modified T cells in cancer therapy. Clin Transl Immunology 2014;3:e16.
42. Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma 1995;18:385–397.
43. Fielding AK, Richards SM, Chopra R et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): An MRC UKALL12/ ECOG 2993 study. Blood 2007;109:944–950.
44. Nguyen K, Devidas M, Cheng SC et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: A Children’s Oncology Group study. Leukemia 2008;22:2142–2150.
45. Ko RH, Ji L, Barnette P et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: A Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol 2010;28:648–654.
46. Wierda WG, O’Brien S, Wang X et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007;109:4679–4685.
47. Gyurkocza B, Rezvani A, Storb RF. Allogeneic hematopoietic cell transplantation: The state of the art. Expert Rev Hematol 2010;3:285–299.
48. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813–1826.
49. Dreger P, Corradini P, Kimby E et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: The EBMT transplant consensus. Leukemia 2007;21:12–17.
50. Dreger P. Allotransplantation for chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2009;602–609.
51. Sorror ML, Storer BE, Sandmaier BM et al. Fiveyear follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008;26: 4912–4920.
52. Laurenti L, Tarnani M, Chiusolo P et al. Allogeneic transplantation for chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis 2010;2: e2010026.
53. Maude S, Shaw P, Aplenc R et al. Chimeric antigen receptor (CAR)-modified T cells targeting CD19 induce sustained remissions in children and young adults with relapsed/refractory ALL. European Hematology Association 2015;Abstract S111 (June 12).
54. Maude SL, Frey N, Shaw PA et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507–1517.
55. Grupp S, Maude S, Shaw P et al. T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) have long term persistence and induce durable remissions in children with relapsed, refractory ALL. Blood 2014;124:380.
56. Porter D, Frey N, Melenhorst J et al. Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL. Blood 2014;124:1982.
57. Schuster S, Svoboda J, Nasta S et al. Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD191 lymphomas. Blood 2014;124:3087.
58. Schuster SJ, Svoboda J, Nasta S et al. Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD191 lymphomas. J Clin Oncol 2015;33(suppl):8516.
59. Frey NV, Levine B, Lacey SF et al. Refractory cytokine release syndrome in recipients of chimeric antigen receptor (CAR) T cells. Blood 2014;124: 2296.
60. Turtle C, Sommermeyer D, Berger C et al. Therapy of B cell malignancies with CD19-specific chimeric antigen receptor-modified T cells of defined subset composition. Blood 2014;124:384.
61. Jensen MC. Advancing CAR T cell immunotherapy in pediatric oncology. AACR Annual Meeting Fourth Annual AACR-PCWG Special Scientific Session: Optimizing Targeted Therapy for Pediatric Cancers. 2015; April 21.
62. Sadelain M. CARs—from assembly to distribution. AACR Annual Meeting Adoptive T-Cell Therapy Major Symposium. 2015; April 21.
63. Curran K, Riviere I, Kobos R et al. Chimeric antigen receptor (CAR) T cells targeting the CD19 antigen for the treatment of pediatric relapsed B cell ALL. Blood 2014;124:3716.
64. Park J, Riviere I, Wang X et al. CD19-targeted 19-28z CAR modified autologous T cells induce high rates of complete remission and durable responses in adult patients with relapsed, refractory B-cell ALL. Blood 2014;124:382.
65. Gardner R, Park J, Kelly-Spratt K et al. T cell products of defined CD4:CD8 composition and prescribed levels of CD19CAR/EGFRT transgene expression mediate regression of acute lymphoblastic leukemia in the setting of post-allo HSCT relapse. Blood 2014;124:3711.
66. Kochenderfer J, Somerville R, Lu L et al. Anti-CD19 CAR T cells administered after lowdose chemotherapy can induce remissions of chemotherapy-refractory diffuse large B-cell lymphoma. Blood 2014;124:550.
67. Kochenderfer JN, Dudley ME, Kassim SH et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015;33:540–549.
68. Lee DW, Kochenderfer JN, Stetler-Stevenson M et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 doseescalation trial. Lancet 2015;385:517–528.
69. Tom B, Dendorfer A, de Vries R et al. Bradykinin potentiation by ACE inhibitors: A matter of metabolism. Br J Pharmacol 2002;137:276–284.
70. Yuan S, Ziman A, Smeltzer B et al. Moderateand severe adverse events associated with apheresis donations: Incidences and risk factors. Transfusion 2010;50:478–486.
71. Davila ML, Riviere I, Wang X et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra25.
72. Davila ML, Bouhassira DC, Park JH et al. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol 2014;99:361–371.
73. Davila ML, Riviere I, Wang X et al. Safe and effective re-induction of complete remissions in adults with relapsed B-ALL using 19-28z CAR CD19- targeted T cell therapy. Blood 2013;122:69.
74. Brentjens RJ, Rivière I, Park JH et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011;118:4817–4828.
75. Jeyarajah DR, Thistlethwaite JR Jr. General aspects of cytokine-release syndrome: Timing and incidence of symptoms. Transplant Proc 1993;25 (suppl 1):16–20.
76. Porter DL, Lacey SF, Hwang W et al. Cytokine release syndrome (CRS) after chimeric antigen recepter (CAR) T cell therapy for relapsed/ refractory (R/R) CLL. Blood 2014;124:1983.
77. Turtle CJ, Hanafi L, Berger C et al. Addition of fludarabine to cyclophosphamide lymphodepletion improves in vivo expansion of CD19 chimeric antigen receptor-modified T cells and clinical outcome in adults with B cell acute lymphoblastic leukemia. Blood 2015;126:3773.
78. Lee DW, Stetler-Stevenson M, Yuan CM et al. Safety and response of incorporating CD19 chimeric antigen receptor T cell therapy in typical salvage regimens for children and young adults with acute lymphoblastic leukemia. Blood 2015;126:684.
79. Schuster SJ, Svoboda J, Nasta SD et al. Sustained remissions following chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD191 lymphomas. Blood 2015;126:183.
80. Sauter CS, Riviere I, Bernal Y et al. PhaseI trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B-cell non- Hodgkin lymphoma (B-NHL). J Clin Oncol 2015;33 (suppl):8515.
81. Locke FL, Neelapu SS, Bartlett NL et al. Phase 1 clinical results of the ZUMA-1 (KTE-C19-101) study: A phase 1-2 multi-center study evaluating the safety and efficacy of anti-CD19 CAR T cells (KTE-C19) in subjects with refractory aggressive non-Hodgkin lymphoma (NHL). Blood 2015;684:3991.
82. Viardot A, Goebeler M, Hess G et al. Treatment of relapsed/refractory diffuse large B-cell lymphoma with the bispecific T-cell engager (BiTE) antibody construct blinatumomab: Primary analysis results from an open-label, phase 2 study. Blood 2014;124:4460.
83. Martinelli G, Dombret H, Chevallier P et al. Complete molecular and hematologic response in adult patients with relapsed/refractory (R/R) Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL) following treatment with blinatumomab: Results from a phase 2 singlearm, multicenter study (ALCANTARA). Blood 2015; 126:679.
84. Kochenderfer JN, Dudley ME, Carpenter RO et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013;122:4129–4139.
85. Porter DL, Levine BL, Kalos M et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl JMed 2011;365:725–733.
86. Porter DL, Kalos M, Frey NV et al. Chimeric antigen receptor modified T cells directed against CD19 (CTL019 cells) have long-term persistence and induce durable responses in relapsed, refractory CLL. Blood 2013;122:4162.
87. Marcus A, Eshhar Z. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer. Expert Opin Biol Ther 2014;14: 947–954.
88. Barber A, Rynda A, Sentman CL. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. J Immunol 2009;183: 6939–6947.
89. Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: Chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev 2014; 257:83–90.
90. Pegram HJ, Lee JC, Hayman EG et al. Tumor targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012;119:4133–4141.
91. Maher J. Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol 2012;2012:278093.
92. Wang GP, Levine BL, Binder GK et al. Analysis of lentiviral vector integration in HIV1 study subjects receiving autologous infusions of gene modified CD41 T cells. Mol Ther 2009;17:844–850.
93. Riet T, Holzinger A, Dörrie J et al. Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapy. Methods Mol Biol 2013;969:187–201.
94. Boissel L, Betancur M, Lu W et al. Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens. Leuk Lymphoma 2012;53: 958–965.
95. Barrett DM, Liu X, Jiang S et al. Regimen specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Hum Gene Ther 2013;24:717–727.
96. Gilham DE, Debets R, Pule M et al. CAR-T cells and solid tumors: Tuning T cells to challenge an inveterate foe. Trends Mol Med 2012;18:377–384.
97. John LB, Kershaw MH, Darcy PK. Blockade of PD-1immunosuppression boosts CART-cell therapy. OncoImmunology 2013;2:e26286.
98. John LB, Devaud C, Duong CP et al. Anti-PD-1 antibody therapy potentlyenhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 2013;19:5636–5646.
99. Sauter C, Riviere I, Bernal Y et al. Interim safety analysis: A phase I trial of high dose therapy and autologous stem cell transplantation followed by infusion of chimeric antigen receptor modified Tcells (19-28z CAR-T) directed against CD191B-cells for relapsed and refractory aggressive B cell non- Hodgkin lymphoma (B-NHL). Blood 014;124:677.